Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma.
biomarkers
miR-375-3p
microRNA
serum
teratoma
testicular germ cell tumour
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
05
09
2019
revised:
05
10
2019
accepted:
05
11
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
3
6
2020
Statut:
ppublish
Résumé
Clinical management of testicular germ cell tumours (GCT) is based upon the measurement of serum tumour markers. Recent studies have shown that the microRNA-371a-3p is a sensitive and specific serum biomarker for all subgroups of GCT, except teratoma. To close the diagnostic gap relating to teratoma, serum levels of microRNA-375-3p have recently been suggested to represent a specific serum marker of this histological subgroup. In the present study, we tested this hypothesis. miRNA expression was analysed in serum of 21 GCT patients with teratoma, twelve patients with other GCT, and twelve male controls using the qPCR method. The serum miR-375-3p levels of teratoma patients were not different from other GCT patients or controls. The ROC analysis revealed an AUC of 0.524 for the discrimination between teratoma and other pathologies. The miR-375-3p does probably not qualify for a useful serum biomarker to distinguish teratoma from other GCTs and from controls.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Clinical management of testicular germ cell tumours (GCT) is based upon the measurement of serum tumour markers. Recent studies have shown that the microRNA-371a-3p is a sensitive and specific serum biomarker for all subgroups of GCT, except teratoma. To close the diagnostic gap relating to teratoma, serum levels of microRNA-375-3p have recently been suggested to represent a specific serum marker of this histological subgroup. In the present study, we tested this hypothesis.
MATERIALS AND METHODS
METHODS
miRNA expression was analysed in serum of 21 GCT patients with teratoma, twelve patients with other GCT, and twelve male controls using the qPCR method.
RESULTS
RESULTS
The serum miR-375-3p levels of teratoma patients were not different from other GCT patients or controls. The ROC analysis revealed an AUC of 0.524 for the discrimination between teratoma and other pathologies.
CONCLUSION
CONCLUSIONS
The miR-375-3p does probably not qualify for a useful serum biomarker to distinguish teratoma from other GCTs and from controls.
Identifiants
pubmed: 31882475
pii: 34/1/163
doi: 10.21873/invivo.11757
pmc: PMC6984070
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN375 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-168Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
J Clin Oncol. 2019 Jun 1;37(16):1412-1423
pubmed: 30875280
Int J Mol Sci. 2019 Jan 10;20(2):null
pubmed: 30634670
Eur Urol. 2008 Feb;53(2):260-72
pubmed: 18045770
Nat Rev Urol. 2016 Dec;13(12):715-725
pubmed: 27754472
Andrology. 2015 Jan;3(1):78-84
pubmed: 25187505
J Clin Oncol. 1995 May;13(5):1177-87
pubmed: 7537801
Biomed Res Int. 2019 May 28;2019:5030349
pubmed: 31275973
Eur Urol. 2015 Dec;68(6):1054-68
pubmed: 26297604
Mol Biol Rep. 2014 Mar;41(3):1257-66
pubmed: 24390317
J Urol. 2018 Jul;200(1):126-135
pubmed: 29474847
J Int Med Res. 2018 Mar;46(3):975-983
pubmed: 29115164
Cancer Genomics Proteomics. 2007 Sep-Oct;4(5):359-67
pubmed: 17993720
Andrology. 2019 Jul;7(4):402-407
pubmed: 30578617
Eur Urol. 2017 Feb;71(2):213-220
pubmed: 27495845
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Histopathology. 2017 Mar;70(4):513-521
pubmed: 27801954
Front Biosci (Landmark Ed). 2019 Mar 1;24:765-776
pubmed: 30844711
Clin Genitourin Cancer. 2019 Feb;17(1):e176-e183
pubmed: 30497810
Anticancer Res. 2014 Jun;34(6):2709-13
pubmed: 24922631
Anticancer Res. 2015 Jan;35(1):117-21
pubmed: 25550541
Curr Pharm Biotechnol. 2014;15(5):486-91
pubmed: 24846060
Mol Med Rep. 2016 Jun;13(6):4643-53
pubmed: 27081922